Nebulised hypertonic (7%) saline improves quality of life in a blinded randomised cross-over trial

F. Kellett, R. Niven, R. Niven (Warrington, United Kingdom)

Source: Annual Congress 2010 - Management of airway disease
Session: Management of airway disease
Session type: Thematic Poster Session
Number: 4572
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. Kellett, R. Niven, R. Niven (Warrington, United Kingdom). Nebulised hypertonic (7%) saline improves quality of life in a blinded randomised cross-over trial. Eur Respir J 2010; 36: Suppl. 54, 4572

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Randomized, double-blind, controlled trial of preventive inhalation of hypertonic saline in infants with CF (PRESIS)
Source: International Congress 2018 – Cystic fibrosis: microbiological aspects and new treatments
Year: 2018



A randomised controlled trial on the effect of inhaled hypertonic saline on quality of life in primary ciliary dyskinesia
Source: Eur Respir J , 49 (2) 1601770; DOI: 10.1183/13993003.01770-2016
Year: 2017



The effect of 3% and 6% hypertonic saline in viral bronchiolitis: a randomised controlled trial
Source: Eur Respir J 2014; 44: 913-921
Year: 2014



Eszopiclone improves the quality of polysomnography: prospective, blinded, placebo-controlled trial
Source: Annual Congress 2008 - Assessment of sleep apnoea
Year: 2008

A multicenter, randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the fluticasone/salmeterol (500/50 μg) combination administered with the new Elpenhaler inhalation device versus the innovative one in patients with asthma
Source: Annual Congress 2009 - Quality of treatment in primary respiratory care
Year: 2009

Short-term effect of a single dose of inhaled procaterol on exercise performance in COPD: a randomized, double blind, placebo-controlled, crossover trial
Source: Annual Congress 2008 - Physiological response to exercise performance
Year: 2008


Glycopyrrolate MDI demonstrates comparable efficacy and safety to tiotropium DPI in a randomized, double-blind, placebo-controlled phase 2b study in patients with COPD
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011

Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD
Source: International Congress 2017 – Bronchodilators and bronchoprotectors
Year: 2017


A single centre, double blind, double dummy, placebo controlled, randomized, three period cross-over phase III trial to demonstrate therapeutic equivalence between a generic and branded inhalation product of ipratropium bromide in subjects with
Source: Eur Respir J 2001; 18: Suppl. 33, 71s
Year: 2001

Inhaled racemic adrenalin versus saline in acute bronchiolitis, a multicenter randomized double-blind clinical trial
Source: Annual Congress 2012 - New insights into respiratory infections in children
Year: 2012

Clinical effect on asthma control using a novel digital self-management solution: a physician blinded randomized controlled crossover trial
Source: International Congress 2019 – Medical education to improve practice
Year: 2019




Randomized, double blind, double dummy, placebo-controlled trial designed for comparing the effectiveness of formoterol (Foradil®) Aerolizer® and ipatropium bromide plus nebulized fenoterol (Berodual®) in asthma patients with ages ranging between 5 and 12 years who suffer acute asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010

A double-blind trial of hyperosmolar saline as an adjunt to phsiotherapy in patients with bronchiectasis
Source: Eur Respir J 2001; 18: Suppl. 33, 484s
Year: 2001

Quality of life in patients with COPD and nocturnal supplemental oxygen-therapy: a prospective, placebo-controlled cross-over trial
Source: Eur Respir J 2005; 26: Suppl. 49, 289s
Year: 2005

Effect of salmetrol-fluticason combination and tiotropium on clinical and physiological improvement of bronchial anthracofibrosis, a double blind randomized, cross over, placebo controlled, clinical trial.
Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology
Year: 2017


Late Breaking Abstract - The impact of regular bisoprolol on recovery with salbutamol in asthma; a double-blind randomised controlled trial
Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies
Year: 2019


A double-blind double dummy randomised placebo-controlled cross-over design clinical trial of formoterol delivered by two different dry powder devices in prevention of bronchoconstriction induced by methacholine in mild to moderate persistent asthma in adult patients
Source: Annual Congress 2009 - Airway hyperresponsiveness: mechanism and assessment
Year: 2009

A randomised, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis
Source: Annual Congress 2008 - Infectious lung diseases including tuberculosis
Year: 2008


A randomized crossover study of sputum induction by physiotherapy and hypertonic saline techniques in asthmatic children
Source: International Congress 2017 – Diagnostic tools and comorbidities in paediatric asthma
Year: 2017